E
Erasca, Inc. (ERAS)
NMS – Real Time Price. Currency in USD
10.38
-0.06 (-0.57%)
At close: May 12, 2026, 4:00 PM EDT
10.42
+0.04 (0.39%)
After-hours: May 12, 2026, 7:49 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
10.38
-0.06 (-0.57%)
At close: May 12, 2026, 4:00 PM EDT
10.42
+0.04 (0.39%)
After-hours: May 12, 2026, 7:49 PM EDT
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. David M. Chacko M.D. | CFO & Chief Business Officer |
| Dr. Jonathan E. Lim M.D. | Co-Founder, Chairman & CEO |
| Dr. Lisa Tesvich-Bonora Ph.D. | Chief People Officer |
| Dr. Michael D. Varney Ph.D. | Chairman of Research & Development, Scientific Advisory Board Member and Director |
| Dr. Nik Chetwyn Ph.D. | Chief Operating Officer |
| Dr. Robert Shoemaker Ph.D. | Chief Scientific Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | 10-Q | eras-20260331.htm |
| 2026-04-28 | DEFA14A | d946335ddefa14a.htm |
| 2026-04-27 | 8-K | d126999d8k.htm |
| 2026-04-21 | 8-K | eras-20260421.htm |
| 2026-03-12 | 10-K | eras-20251231.htm |
| 2026-01-29 | 8-K | eras-20260129.htm |
| 2026-01-22 | 8-K | d51429d8k.htm |
| 2026-01-12 | 8-K | eras-20260112.htm |
| 2025-11-12 | 10-Q | eras-20250930.htm |
| 2025-08-20 | CORRESP | filename1.htm |
| Dr. Shannon R. Morris M.D., Ph.D. | Chief Medical Officer |
| Mr. Brian L. Baker CPA, M.S. | Senior Vice President of Finance |
| Mr. Ebun S. Garner Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Chandra D. Lovejoy M.S. | Chief Regulatory Affairs Officer |